Literature DB >> 8445708

The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.

X Lu1, T M Welsh, B M Peterlin.   

Abstract

The human immunodeficiency virus type 1 long terminal repeat sets up two different transcription complexes, which have been called processive and nonprocessive complexes. By mutating and substituting cis-acting sequences, we mapped elements of the human immunodeficiency virus long terminal repeat that are responsible for creating each transcription complex. Whereas processive complexes are efficiently assembled by upstream promoter elements in the absence of the TATA box, nonprocessive complexes absolutely require the TATA box. Moreover, the TATA box alone can set up these nonprocessive complexes, and nonprocessive but not processive complexes are trans activated by Tat. Finally, a strong DNA-binding site between the TATA box and trans-activation-responsive region interferes with either the assembly or movement of these nonprocessive complexes and diminishes the effects of Tat. Thus, Tat affects a critical step in the formation of elongation-competent transcription complexes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445708      PMCID: PMC240213     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

3.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

Authors:  B M Peterlin; P A Luciw; P J Barr; M D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.

Authors:  M A Muesing; D H Smith; D J Capon
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

6.  Selective and accurate initiation of transcription at the Ad2 major late promotor in a soluble system dependent on purified RNA polymerase II and DNA.

Authors:  P A Weil; D S Luse; J Segall; R G Roeder
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

7.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

Review 8.  Regulation of SV40 early gene expression.

Authors:  A G Wildeman
Journal:  Biochem Cell Biol       Date:  1988-06       Impact factor: 3.626

9.  Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters.

Authors:  K A Jones; P A Luciw; N Duchange
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

10.  The RNA polymerase II molecule at the 5' end of the uninduced hsp70 gene of D. melanogaster is transcriptionally engaged.

Authors:  A E Rougvie; J T Lis
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

View more
  46 in total

1.  Upstream and downstream sequence elements determine the specificity of the rice tungro bacilliform virus promoter and influence RNA production after transcription initiation.

Authors:  A Klöti; C Henrich; S Bieri; X He; G Chen; P K Burkhardt; J Wünn; P Lucca; T Hohn; I Potrykus; J Fütterer
Journal:  Plant Mol Biol       Date:  1999-05       Impact factor: 4.076

2.  Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.

Authors:  C Suñé; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1.

Authors:  A C Goldstrohm; T R Albrecht; C Suñé; M T Bedford; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 4.  The unexpected traits associated with core promoter elements.

Authors:  Rivka Dikstein
Journal:  Transcription       Date:  2011 Sep-Oct

Review 5.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

6.  Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing.

Authors:  Huimin Jiang; Fan Zhang; Takeshi Kurosu; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

7.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

9.  Differential regulation of NF-kappaB by elongation factors is determined by core promoter type.

Authors:  Liat Amir-Zilberstein; Elena Ainbinder; Leanne Toube; Yuki Yamaguchi; Hiroshi Handa; Rivka Dikstein
Journal:  Mol Cell Biol       Date:  2007-05-14       Impact factor: 4.272

10.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.